Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Direxion Daily CSI China Internet Bull 2X Shares (CWEB) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Direxion Daily CSI China Internet Bull 2X SharesTrade
Regeneron Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Direxion Daily CSI China Internet Bull 2X Shares vs Regeneron Pharmaceuticals Inc — how do they compare? Direxion Daily CSI China Internet Bull 2X Shares trades at $24.61, while Regeneron Pharmaceuticals Inc trades at $790 (market cap $83.19B). The key difference: Regeneron Pharmaceuticals Inc pays a 0.47% dividend while Direxion Daily CSI China Internet Bull 2X Shares pays none, and Regeneron Pharmaceuticals Inc is trading nearer its 52-week high, Direxion Daily CSI China Internet Bull 2X Shares nearer its low. Which is the better fit depends on your goals.

CWEBREGN
Sector
Leveraged / InverseHealth
52-Week High
$60.13$812.27
52-Week Low
$17.70$545.94
Market Cap
$83.19B
Enterprise Value
$77.90B
Dividend Yield
0.47%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Direxion Daily CSI China Internet Bull 2X Shares

CWEB trades at $25.53, up 1.67% today, with a bullish technical signal from moving averages. The stock shows strong momentum indicators but an overbought short-term RSI. A dividend of $0.09 is scheduled for June 2026, reflecting potential income return. Recent news highlights renewed interest in China growth stocks, which may benefit CWEB's positioning.

The outlook for CWEB is cautiously optimistic, driven by positive technical trends and sector sentiment. Key risks include reliance on China market dynamics and potential volatility. Investment opportunity lies in growth stock resurgence, but investors must weigh macroeconomic and regulatory uncertainties in the region.

Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.

Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Direxion Daily CSI China Internet Bull 2X Shares

CWEB is a leveraged ETF that seeks to provide two times (2x) the daily performance of the CSI China Internet Index. It offers magnified exposure to top Chinese internet companies listed on US and Hong Kong exchanges.

Read more on CWEB

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases

Read more on REGN